Pregnancy outcome of FVQ/QThbdPro/+ females mated to ThbdPro/+ males
| Stage of analysis . | Parental genotype . | Genotype of live embryos (number/%) . | Number (%) of aborted embryos . | Number of embryos/ pregnancies analyzed . | |||
|---|---|---|---|---|---|---|---|
| Female . | Male . | FVQ/+Thbd+/+ . | FVQ/+ThbdPro/+ . | FVQ/+ThbdPro/Pro . | |||
| 15.5 dpc | FVQ/QThbdPro/+ | ThbdPro/+ | 20 (42.6%) | 27 (57.4%) | 0* | 42 (47.2%) | 89 (9) |
| 15.5 dpc | ThbdPro/+ | FVQ/QThbdPro/+ | 26 (29.5%) | 38 (43.2%) | 24 (27.3%) | 4 (4.3%) | 92 (10) |
| 15.5 dpc | Par3−/− | ThbdPro/+ | 14 (26.4%) | 31 (58.5%) | 8 (15.1%) | 24 (31.2%) | 77 (8) |
| FVQ/QThbdPro/+ | |||||||
| Neonates | Par3−/− | ThbdPro/+ | 16 (22.9%) | 38 (54.3%) | 16 (22.9%) | — | 70 (9) |
| FVQ/QThbdPro/+ | |||||||
| Neonates | Par4−/− | ThbdPro/+ | 7 (20%) | 22 (62.9%) | 6 (17.1%) | — | 35 (7) |
| FVQ/QThbdPro/+ | |||||||
| 15.5 dpc | β3LA/LA | ThbdPro/+ | 19 (25%) | 32 (42.1%) | 0* | 25 (32.9%) | 76 (9) |
| FVQ/QThbdPro/+ | |||||||
| Stage of analysis . | Parental genotype . | Genotype of live embryos (number/%) . | Number (%) of aborted embryos . | Number of embryos/ pregnancies analyzed . | |||
|---|---|---|---|---|---|---|---|
| Female . | Male . | FVQ/+Thbd+/+ . | FVQ/+ThbdPro/+ . | FVQ/+ThbdPro/Pro . | |||
| 15.5 dpc | FVQ/QThbdPro/+ | ThbdPro/+ | 20 (42.6%) | 27 (57.4%) | 0* | 42 (47.2%) | 89 (9) |
| 15.5 dpc | ThbdPro/+ | FVQ/QThbdPro/+ | 26 (29.5%) | 38 (43.2%) | 24 (27.3%) | 4 (4.3%) | 92 (10) |
| 15.5 dpc | Par3−/− | ThbdPro/+ | 14 (26.4%) | 31 (58.5%) | 8 (15.1%) | 24 (31.2%) | 77 (8) |
| FVQ/QThbdPro/+ | |||||||
| Neonates | Par3−/− | ThbdPro/+ | 16 (22.9%) | 38 (54.3%) | 16 (22.9%) | — | 70 (9) |
| FVQ/QThbdPro/+ | |||||||
| Neonates | Par4−/− | ThbdPro/+ | 7 (20%) | 22 (62.9%) | 6 (17.1%) | — | 35 (7) |
| FVQ/QThbdPro/+ | |||||||
| 15.5 dpc | β3LA/LA | ThbdPro/+ | 19 (25%) | 32 (42.1%) | 0* | 25 (32.9%) | 76 (9) |
| FVQ/QThbdPro/+ | |||||||
ThbdPro/Pro embryos die in midgestation in pregnancies carried by FVQ/QThbdPro/+ mothers (row 1), but survive in the reverse genetic cross (row 2) in pregnancies carried by FV+/+ mothers. Attenuation of thrombin signaling by genetic absence of Par3 in the mother allows survival of several ThbdPro/Pro embryos (row 3) and neonates (row 4) in these pregnancies, as does the genetic absence of maternal Par4 (row 5). Attenuation of maternal platelet aggregation (row 6) does not result in comparable rescue. Based on Mendelian inheritence, Thbd+/+, ThbdPro/+, and ThbdPro/Pro embryos are expected to be born at 25%, 50%, and 25% proportions, respectively, from these crosses.
There is a significant difference from expected proportions (P value < .05) based on the χ2 GOF test.